Search Results - "Liguigli, Wanda"

Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) by Cosmai, Laura, Gallieni, Maurizio, Liguigli, Wanda, Porta, Camillo

“…Since angiogenesis plays a key role in tumor growth, progression and metastasization, anti-vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)…”
Get full text

Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity by Porta, Camillo, Giglione, Palma, Liguigli, Wanda, Paglino, Chiara

“…Dovitinib is an oral multikinase inhibitor targeting FGF receptors, PDGF receptors and VEGF receptors. Its activity against FGF receptors suggests its…”
Get full text

Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial by Tomasello, Gianluca, Liguigli, Wanda, Poli, Rossana, Lazzarelli, Silvia, Brighenti, Matteo, Negri, Federica, Curti, Alessandra, Martinotti, Mario, Olivetti, Lucio, Rovatti, Massimo, Donati, Gianvito, Passalacqua, Rodolfo

“…Background We previously studied a dose-dense TCF (TCF-dd) regimen demonstrating its feasibility and an activity comparable to epirubicin-based chemotherapy…”
Get full text

Pharmacotherapy for treating metastatic clear cell renal cell carcinoma by Porta, Camillo, Chiellino, Silvia, Ferrari, Alessandra, Mariucci, Sara, Liguigli, Wanda

“…Over the past decade metastatic renal cell carcinoma (RCC) treatment landscape has dramatically evolved from the era of cytokines-based immunotherapy (which…”
Get more information

Targeted therapies in gastric cancer treatment: where we are and where we are going by Tomasello, Gianluca, Ghidini, Michele, Liguigli, Wanda, Ratti, Margherita, Toppo, Laura, Passalacqua, Rodolfo

“…Summary Gastric cancer (GC) is one of the most common malignancies and a major cause of cancer-related deaths worldwide. Its incidence has significantly…”
Get full text

Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial by Liguigli, Wanda, Tomasello, Gianluca, Toppo, Laura, Ratti, Margherita, Passalacqua, Rodolfo

“…Gastric cancer is a highly aggressive disease. In metastatic setting, median overall survival, even with modern chemotherapy regimens, generally does not…”
Get more information

Tivantinib (ARQ197) in hepatocellular carcinoma by Porta, Camillo, Giglione, Palma, Ferrari, Alessandra, Reversi, Francesca, Liguigli, Wanda, Imarisio, Ilaria, Ganini, Carlo

“…Here we review the development of tivantinib, a selective oral inhibitor of c-MET. The initially identified dose and schedule for clinical use was 360 mg twice…”
Get full text

Phase II study of tivantinib (ARQ 197) and cetuximab in patients with EGFR inhibitor-resistant, MET-High, KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC) by Rimassa, Lorenza, Bozzarelli, Silvia, Cordio, Stefano, Pietrantonio, Filippo, Toppo, Laura, Lonardi, Sara, Zaniboni, Alberto, Bordonaro, Roberto, Di Bartolomeo, Maria, Liguigli, Wanda, Zagonel, Vittorina, Tronconi Maria, Chiara, Di Tommaso, Luca, Giordano, Laura, Santoro, Armando

Get full text

Presence of bone metastases(BM) at diagnosis is associated with poor prognosis and coagulation disorders (CD) in patients (pts) with advanced gastric cancer (AGC) by Toppo, Laura, Liguigli, Wanda, Senti, Chiara, Tomasello, Gianluca, Ghidini, Michele, Ratti, Margherita, Botticelli, Andrea, Onesti, Concetta Elisa, DI Pietro, Francesca, Pizzo, Claudio, Panni, Stefano, Curti, Alessandra, Passalacqua, Rodolfo

“…Abstract only e15538 Background: The presence of BM in AGC is a relatively uncommon finding and has a poor prognosis [Leporini C. 2015]. At diagnosis the…”
Get full text

Bone metastases (BM) in patients (pts) with locally advanced or metastatic gastric cancer (AGC): Clinical and therapeutic implications by Liguigli, Wanda, Toppo, Laura, Tomasello, Gianluca, Poli, Rossana, Ratti, Margherita, Lazzarelli, Silvia, Donida, Bianca Maria, Passalacqua, Rodolfo

“…Abstract only…”
Get full text

First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5- fluorouracil (DCF) plus panitumumab (P) in patients with locally advanced or metastatic cancer of the stomach or gastro-esophageal junction: Updated results of a phase II multicenter trial by Tomasello, Gianluca, Liguigli, Wanda, Toppo, Laura, Negri, Federica, Curti, Alessandra, Ratti, Margherita, Poli, Rossana, Lazzarelli, Silvia, Gerevini, Fabiana, Colombi, Chiara, Rovatti, Massimo, Olivetti, Lucio, Martinotti, Mario, Passalacqua, Rodolfo

“…Abstract only…”
Get full text

Modified dose-dense taxotere cisplatin fluorouracil regimen (mTCF-dd) in a large cohort of patients (pts) with metastatic or locally advanced non-squamous gastroesophageal cancer (GEC) by Toppo, Laura, Tomasello, Gianluca, Liguigli, Wanda, Lazzarelli, Silvia, Tanzi, Giulia, Ghidini, Michele, Perrucci, Bruno, Brighenti, Matteo, Ratti, Margherita, Panni, Stefano, Giganti, Maria Olga, Donini, Maddalena, Rovatti, Massimo, Maglietta, Giuseppe, Ranieri, Valerio, Grassia, Roberto, Iiritano, Elena, Iezzi, ELISA, Caminiti, Caterina, Passalacqua, Rodolfo

“…Abstract only…”
Get full text

First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study by Tomasello, Gianluca, Valeri, Nicola, Ghidini, Michele, Smyth, Elizabeth C, Liguigli, Wanda, Toppo, Laura, Mattioli, Rodolfo, Curti, Alessandra, Hahne, Jens C, Negri, Federica M, Panni, Stefano, Ratti, Margherita, Lazzarelli, Silvia, Gerevini, Fabiana, Colombi, Chiara, Panni, Andrea, Rovatti, Massimo, Treccani, Leonardo, Martinotti, Mario, Passalacqua, Rodolfo

“…Survival for patients with advanced gastroesophageal cancer (AGC) using standard treatment regimens is poor. EGFR overexpression is common in AGC and…”
Get full text

Nab-paclitaxel (nab-p) in association with FOLFIRI (Nab-FOLFIRI) or FOLFOX (Nab-FOLFOX) for metastatic pancreatic cancer: A phase I/II trial by Italian Oncology Group for Clinical Research (GOIRC)—NabucCO Trial by Giommoni, Elisa, Maiello, Evaristo, Toppo, Laura, Cognetti, Francesco, Tortora, Giampaolo, Febbraro, Antonio, Banzi, Maria, Molinara, Elena, Nanni, Luciano, Lamperini, Cinzia, Liguigli, Wanda, Laface, Rosa, Vaccaro, Vanja, Antonuzzo, Lorenzo, Melisi, Davide, Fanello, Silvia, Giordano, Guido, Boni, Luca, Di Costanzo, Francesco

“…Abstract only…”
Get full text

Optimizing chemotherapy in patients with metastatic transitional-cell carcinoma: High rate of complete response with two sequential dose-dense regimens of cisplatin, gemcitabine, paclitaxel, followed by MVAC by Passalacqua, Rodolfo, Giganti, Maria Olga, Brighenti, Matteo, Perrucci, Bruno, Donini, Maddalena, Negri, Federica, Tomasello, Gianluca, Toppo, Laura, Liguigli, Wanda, Poli, Rossana, Ratti, Margherita, Benecchi, Luigi, Prati, Andrea, Arnaudi, Roberto, Potenzoni, Michele, Panni, Stefano, Lazzarelli, Silvia

“…Abstract only 303 Background: Currently, cisplatin, gemcitabine, paclitaxel (CGP) and MVAC are the most active regimens in transitional-cell carcinoma (TCC)…”
Get full text

First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5- fluorouracil (DCF) plus panitumumab (P) in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction (GEJ): A phase II multicenter trial by Tomasello, Gianluca, Liguigli, Wanda, Toppo, Laura, Mattioli, Rodolfo, Negri, Federica, Curti, Alessandra, Ratti, Margherita, Poli, Rossana, Lazzarelli, Silvia, Gerevini, Fabiana, Colombi, Chiara, Martinotti, Mario, Rovatti, Massimo, Olivetti, Lucio, Passalacqua, Rodolfo

“…Abstract only 146 Background: Gastric cancer is a highly aggressive disease. No established standard first-line regimens are currently available. Aim of this…”
Get full text

Safety and Efficacy of Dose-dense Chemotherapy with TCF Regimen in Elderly Patients with Locally Advanced or Metastatic Gastric Cancer by Liguigli, Wanda, Tomasello, Gianluca, Toppo, Laura, Poli, Rossana, Lazzarelli, Silvia, Negri, Federica, Perrucci, Bruno, Curti, Alessandra, Brighenti, Matteo, Donati, Gianvito, Nazzari, Morena, Martinotti, Mario, Vismarra, Marco, Rovatti, Massimo, Passalacqua, Rodolfo

“…Purpose To evaluate the efficacy and safety of dose-dense TCF in elderly (≥65 years) compared to younger patients. Methods Safety and efficacy data relative to…”
Get full text

Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by oxaliplatin, folinic acid, 5-fluorouracil, and irinotecan (COFFI) in locally advanced or metastatic gastric cancer (MGC) by Tomasello, Gianluca, Liguigli, Wanda, Poli, Rossana, Negri, Federica, Brighenti, Matteo, Toppo, Laura, Curti, Alessandra, Lazzarelli, Silvia, Panni, Stefano, Donini, Maddalena, Maltese, Mariangela, Ratti, Margherita, Passalacqua, Rodolfo

“…Abstract only 4097 Background: MGC is a chemosensitive tumour. According to the Norton-Simon hypothesis, a reduction of tumor burden could best be achieved by…”
Get full text

Final analysis of efficacy and safety of dose-dense chemotherapy with modified TCF regimen (TCF-dd) in elderly patients (pts) with metastatic gastric cancer (MGC) by Tomasello, Gianluca, Liguigli, Wanda, Poli, Rossana, Ratti, Margherita, Toppo, Laura, Brighenti, Matteo, Maltese, Mariangela, Perrucci, Bruno, Panni, Stefano, Negri, Federica, Lazzarelli, Silvia, Colombi, Chiara, Curti, Alessandra, Donini, Maddalena, Martinotti, Mario, Rovatti, Massimo, Passalacqua, Rodolfo

“…Abstract only e15086 Background: Gastric cancer is more common in elderly pts with its highest incidence around the seventh decade of life. Most oncologists…”
Get full text

Efficacy and safety of dose-dense modified TCF regimen (TCF-dd) in metastatic or locally advanced gastroesophageal cancer (GEC) by Toppo, Laura, Tomasello, Gianluca, Liguigli, Wanda, Ratti, Margherita, Poli, Rossana, Negri, Federica, Curti, Alessandra, Vismarra, Marco, Maltese, Mariangela, Delfrate, Roberto, Donini, Maddalena, Colombi, Chiara, Brighenti, Matteo, Panni, Stefano, Perrucci, Bruno, Lazzarelli, Silvia, Passalacqua, Rodolfo

“…Abstract only 4112 Background: TCF is a standard first line option for GEC. The Norton-Simon hypothesis suggests that chemotherapy efficacy can be enhanced by…”
Get full text